复宏汉霖联手奥鸿药业推进复妥宁 商业化进程

Group 1 - The core point of the article is the collaboration between Fuhong Hanlin and Aohong Pharmaceutical to accelerate the commercialization of the innovative small molecule CDK4/6 inhibitor, Fovetizumab (brand name: Fuzhuoning) [1] - Fuzhuoning has been approved in China for use in patients with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have either received initial endocrine therapy or have progressed after prior endocrine treatment [1] - Aohong Pharmaceutical developed Fuzhuoning, while Fuhong Hanlin holds exclusive commercialization rights in China [1]